PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial

BACKGROUND: Positron emission tomography targeting the prostate specific membrane antigen (PSMA PET/CT) has demonstrated unparalleled performance as a staging examination for prostate cancer resulting in substantial changes in management. However, the impact of altered management on patient outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Ménard, Cynthia, Young, Sympascho, Zukotynski, Katherine, Hamilton, Robert J., Bénard, François, Yip, Steven, McCabe, Christopher, Saad, Fred, Brundage, Michael, Nitulescu, Roy, Bauman, Glenn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902723/
https://www.ncbi.nlm.nih.gov/pubmed/35260100
http://dx.doi.org/10.1186/s12885-022-09283-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902723/
https://www.ncbi.nlm.nih.gov/pubmed/35260100
http://dx.doi.org/10.1186/s12885-022-09283-z

Ejemplares similares